Background: Increased triglycerides (TG) are associated with atherosclerosis. We determined free-living non-fasting TG concentrations in healthy Dutch subjects.
Methods: Capillary TG (TGc) was self-measured by 109 males and 104 females during 3 days, on six fixed time-points each day; fasting, before and 3 h after lunch, before and 3 h after dinner and at bedtime. Daylong TGc-profiles were calculated as area under the mean TGc-curve (TGc-AUC). Reference values for "high" and "normal" daylong TGc concentrations were calculated as the 95th and 75th percentiles, respectively.
Results: Fasting TGc were higher in males compared with females (1.41+/-0.75 versus 1.27+/-0.59 mmol/l), resulting in higher TGc-AUC (25.4+/-10.4 versus 20.6+/-9.8 mmol h/l). The highest TGc-concentrations were found in the evening. The majority of subjects (95%) had TGc during the evening below 4.6 mmol/l in males and below 3.7 mmol/l in females. Seventy-five percent of the subjects had TGc during the evening below 2.9 mmol/l in males and below 2.2 mmol/l in females. During the day (with exclusion of post-dinner TGc), 95% of the subjects had TGc below 3.7 mmol/l in males and below 3.6 mmol/l in females. Finally, 75% of the subjects had TGc during the day below 2.5 mmol/l in males and 1.7 mmol/l in females.
Conclusions: The present data may help to delineate normal ranges of non-fasting TG and could be used to detect groups at risk for atherosclerosis on the basis of a disturbed TG metabolism.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cccn.2003.07.014 | DOI Listing |
BMC Neurol
January 2025
Neurological Disorder Center, Department of Cerebrovascular Disease, Suining Central Hospital, Sichuan, 629000, China.
Background: Hyponatremia (< 135 mmol/L) is the most common electrolyte disturbance in patients with stroke. However, few studies have reported the relationship between hyponatremia at admission and outcomes in patients with acute ischemic stroke (AIS) treated with mechanical thrombectomy (MT). This study is aimed to explore the association between hyponatremia and clinical outcomes following MT.
View Article and Find Full Text PDFDrugs Real World Outcomes
January 2025
Department of Cardiology, Angiology and Intensive Care Medicine, German Heart Center of the Charité, Berlin, Germany.
Background: Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-injection administration.
Methods And Objectives: Monthly application of 300 mg AlirRocumab (Praluent) using the 2-mL SYDNEY Device (MARS) is a non-interventional, open, prospective, multi-center cohort study conducted in Germany between 2021 and 2023 with an observational period of 12 weeks.
Ann Rheum Dis
January 2025
Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. Electronic address:
Objectives: The dynamics of monosodium urate (MSU) crystal changes across a range of serum urate concentrations in people with gout are unknown. This study aimed to systematically examine the relationship between serum urate and changes in dual-energy CT (DECT) urate volume in people with gout and stable serum urate concentrations.
Methods: Individual participant data were analysed from three studies of people with gout.
Heart Vessels
January 2025
Division of Cardiology, Mitsui Memorial Hospital, Kanda-Izumicho 1, Chiyoda-ku, Tokyo, 101-8643, Japan.
The concomitant use of IMPELLA and veno-arterial extracorporeal membrane oxygenation (V-A ECMO) (ECPELLA) has been increasingly used to treat severe cardiogenic shock. However, the relationship between severity of heart failure on admission and prognosis based on differences in the mechanical circulatory support (MCS) is not fully understood. This study evaluated the association between lactate levels on admission and clinical outcomes based on differences in MCS.
View Article and Find Full Text PDFJ Intensive Med
January 2025
Department of Critical Care Medicine, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Trauma Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
Background: Extracorporeal membrane oxygenation (ECMO) has been proven to be a support method and technology for patients with cardiopulmonary failure. However, the transport of patients under ECMO support is challenging given the high-risk technical maneuvers and patient-care concerns involved. Herein, we examined the safety of ECMO during the transport of critically ill patients and its impact on mortality rates, to provide more secure and effective transport strategies in clinical practice.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!